2012 ended up being two years: before Facebook IPO and after. All the enthusiasm, hype, and expectations for the Facebook IPO were shattered even though it ended up being one of the biggest venture backed IPO’s ever. The fallout was so extreme that 2013 is now being billed as the Star Trek year: the Enterprise is back. Is this just the venture spin machine working its magic or will we see a major shift from consumer to enterprise investment? Even with all the well-publicized problems in cleantech, biotech, and medical devices, VCs invested $26B and raised $21B in 2012. What can we expect to see in 2013? What has changed in fundraising? Is there a Series A crunch? What are the key metrics for losing a round? Join this discussion with four outspoken leading investors, as they opine on these key questions and more.
ATTENTION CORPORATE MEMBERS! Corporate passes will be accepted for this event. We ask that if you register using corporate passes, please do so 72 business hours in advance. We thank you for your cooperation!
Sponsored by Microsoft, Womble Carlyle
Andrew Chung, Partner, Khosla Ventures
Jeff Clavier, Founder and Managing Partner, SoftTech VC
John Lilly, Partner, Greylock
Jonathan MacQuitty, Partner, Abingworth Life Science
Peter Sonsini, General Partner, NEA
Steve Bengston, Managing Director, Emerging Company Services, PwC